VitaSpring Biomedical Co. Ltd.
VSBC
$0.01
-$0.24-95.56%
OTC PK
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 10/31/2022 | 10/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 28.28% | 102.64% | 35.44% | 16.13% | 16.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.28% | 102.64% | -73.44% | -45.81% | -45.72% |
| Operating Income | -28.28% | -102.64% | -188.78% | -33.02% | -33.24% |
| Income Before Tax | -27.79% | -102.64% | -186.63% | -33.53% | -33.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.92% | -145.39% | -210.08% | -0.36% | -0.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.92% | -145.39% | -210.08% | -0.36% | -0.58% |
| EBIT | -28.28% | -102.64% | -188.78% | -33.02% | -33.24% |
| EBITDA | -28.80% | -104.92% | -186.71% | -34.03% | -34.26% |
| EPS Basic | -57.14% | -142.86% | -215.38% | 0.00% | 0.00% |
| Normalized Basic EPS | -16.67% | -120.00% | -181.82% | -50.00% | -50.00% |
| EPS Diluted | -57.14% | -142.86% | -215.38% | 0.00% | 0.00% |
| Normalized Diluted EPS | -16.67% | -120.00% | -181.82% | -50.00% | -50.00% |
| Average Basic Shares Outstanding | 0.25% | 0.25% | 0.25% | 0.52% | 0.52% |
| Average Diluted Shares Outstanding | 0.25% | 0.25% | 0.25% | 0.52% | 0.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |